Somatogen, Inc.

Baxter Biotech Technology Sarl

Spencer J Anthony-Cahill

David C Anderson

Antony James Mathews

Bruce A Kerwin

Stephen P Trimble

Janet K Epp

Peter O Olins

Gary L Stetler

Maura-Ann H Matthews

Dominic G Madril

David A Marquardt

The present invention relates to globins containing non-naturally occurring binding domains, In particular, the present invention is directed toward a binding domain comprising the oligomerizing domain GCN4 and GCN4 derivatives. Thc present invention also relates to multimeric hemoglobins comprised of at least one globin containing at least one non-naturally occurring binding domain.

Globins containing binding domains

Modified hemoglobin-like compounds and methods of purifying same

The present invention relates to modified hemoglobin-like compounds. The novel compounds include a globin-like polypeptide containing at least two di-alpha domains and multimeric hemoglobin-like proteins having a core hemoglobin-like moiety directly attached to at least two other hemoglobin-like moieties. The invention also relates to nucleic acid molecules encoding the novel polypeptides. Methods of making the multimeric hemoglobin-like proteins are also provided, as well as compositions containing the proteins.

Modified hemoglobin-like compounds

The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.

Peptide inhibitors of tax-dependent transcription

Growing community of inventors

Bellingham, WA, United States of America

Spencer J Anthony-Cahill